Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | FABP3 | P05413 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6166638 | 0.94 | ACLY (0.44) | CA12CA2CA9DHODHMAOB | |
| SCHEMBL6622607 | 0.94 | HCAR2 (0.47) | CA12CA2CA9DHODHMAOB | |
| SCHEMBL6164397 | 0.93 | PTPN1 (0.50) | CA12CA2CA9MAOBMGLL | |
| SCHEMBL6166691 | 0.90 | MAOB (0.47) | MAOBMEN1NPC1RAB9AKMT2A | |
| SCHEMBL6163347 | 0.89 | TRPM2 (0.48) | CA12CA2CA9MAOBMEN1 | |
| SCHEMBL5774221 | 0.89 | KDM4C (0.47) | MAOB | |
| SCHEMBL6166379 | 0.89 | MGLL (0.48) | MAOBHCAR2MGLLPTPN1FFAR1 | |
| SCHEMBL6164514 | 0.89 | MGLL (0.48) | MAOBHCAR2MGLLPTPN1FFAR1 | |
| SCHEMBL6164836 | 0.86 | SUCNR1 (0.46) | MAOBSUCNR1MGLLFFAR1FFAR4 | |
| SCHEMBL6162827 | 0.86 | MAOB (0.43) | CA12CA2CA9MAOBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379516-B1 | ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-11-16 | — | — | EP | disclosed |
| US-6903086-B2 | Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists | SYNTEX (U.S.A.) LLC (US) | 2005-06-07 | — | — | US | disclosed |
| EP-1379516-A1 | ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-20020165235-A1 | Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists | SYNTEX (U.S.A.) LLC | 2002-11-07 | — | — | US | disclosed |
| WO-2002070500-A1 | ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165235-A1 | Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists | GPBAR1, GABRP, TBXA2R | CA12 3979/4885CA2 618/4885CA9 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.